Tasquinimod failure sends Ipsen and Active Biotech shares tumbling
This article was originally published in Scrip
Executive Summary
Active Biotech and Ipsen have dropped development of the immunotherapy candidate tasquinimod in prostate cancer after its "unambiguous" failure in a Phase III trial.